Cite
HARVARD Citation
Gao, J. et al. (2021). Overall survival in patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer treated with a cyclin-dependent kinase 4/6 inhibitor plus fulvestrant: a US Food and Drug Administration pooled analysis. Lancet oncology. 22 (11), pp. 1573-1581. [Online].